New drug RGT-61159 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called RGT-61159 in people with two types of cancer that have come back or not responded to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to check the drug's safety, find the be…
Phase: PHASE1 • Sponsor: Rgenta Therapeutics Inc • Aim: Disease control
Last updated May 07, 2026 18:41 UTC